A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas.

Kelly, RJ; Abrams, TA; Catenacci, DVT; Wainberg, ZA; Lin, BSL; Enstrom, A; Whiting, CC; Wason, P; Murphy, A; Brockstedt, DG; Moon, A; Walling, J; Lai, R; Ku, GY

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (4):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索